Genmab learns costly lesson of zalutumumab
This article was originally published in Scrip
Executive Summary
"In future we will listen to what big pharma is telling us and concentrate on novel and heavily differentiated products." So said David Eatwell, Genmab's CFO, after the firm announced it would shelve its Phase III anticancer antibody zalutumumab because it had failed to secure a partnership deal (scripintelligence.com, 24 June 2011).